Literature DB >> 3144286

The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).

R J Knox1, M P Boland, F Friedlos, B Coles, C Southan, J J Roberts.   

Abstract

A nitroreductase enzyme has been isolated from Walker 256 rat carcinoma cells which can convert 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to a cytotoxic DNA interstrand crosslinking agent by reduction of its 4-nitro group to the corresponding hydroxylamino species (Roberts JJ et al., Biochem Biophys Res Commun 140: 1073-1078, 1986; Knox RJ et al., Biochem Pharmacol 37: 4661-4669, 1988). The enzyme has now been identified as a form of NAD(P)H dehydrogenase (quinone) (DT diaphorase, menadione reductase (NMOR), phylloquinone reductase, quinone reductase, EC 1.6.99.2) by comparison of partial protein sequences, coenzymes, substrate and inhibitor specificities, and spectroscopic data. 2-Phenyl-5(4)-aminoimidazole-4(5)-carboxamide and 5(4)-aminoimidazole-4(5)-carboxamide were shown to be inhibitors of the isolated Walker cell enzyme. This observation could explain the reported antagonistic action of the aminoimidazole carboxamides to the antitumour effects of CB 1954.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144286     DOI: 10.1016/0006-2952(88)90336-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Functional Annotation of a Presumed Nitronate Monoxygenase Reveals a New Class of NADH:Quinone Reductases.

Authors:  Jacob Ball; Francesca Salvi; Giovanni Gadda
Journal:  J Biol Chem       Date:  2016-08-08       Impact factor: 5.157

Review 3.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

4.  Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.

Authors:  Toru Shibata; Amato J Giaccia; J Martin Brown
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

5.  Modulation of nitro-fatty acid signaling: prostaglandin reductase-1 is a nitroalkene reductase.

Authors:  Dario A Vitturi; Chen-Shan Chen; Steven R Woodcock; Sonia R Salvatore; Gustavo Bonacci; Jeffrey R Koenitzer; Nicolas A Stewart; Nobunao Wakabayashi; Thomas W Kensler; Bruce A Freeman; Francisco J Schopfer
Journal:  J Biol Chem       Date:  2013-07-22       Impact factor: 5.157

Review 6.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  R J Knox; F Friedlos; M P Boland
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 7.  Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

Authors:  W A Denny; W R Wilson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

8.  Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours.

Authors:  Alexandra M Mowday; Ludwig J Dubois; Aleksandra M Kubiak; Jasmine V E Chan-Hyams; Christopher P Guise; Amir Ashoorzadeh; Philippe Lambin; David F Ackerley; Jeff B Smaill; Nigel P Minton; Jan Theys; Adam V Patterson
Journal:  Cancer Gene Ther       Date:  2021-02-08       Impact factor: 5.987

9.  Enamine N-Oxides: Synthesis and Application to Hypoxia-Responsive Prodrugs and Imaging Agents.

Authors:  Dahye Kang; Sheldon T Cheung; Andrew Wong-Rolle; Justin Kim
Journal:  ACS Cent Sci       Date:  2021-03-29       Impact factor: 14.553

Review 10.  Cellular responses to oxidative stress: the [Ah] gene battery as a paradigm.

Authors:  D W Nebert; D D Petersen; A J Fornace
Journal:  Environ Health Perspect       Date:  1990-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.